Light triggers death switch in cancer cells

October 16, 2013

Researchers at Cardiff University have created a peptide (a small piece of protein), linked to a light-responsive dye, capable of switching 'on' death pathways in cancer cells. The peptide remains inactive until exposed to external light pulses which convert it into a cell death signal.

Complex mechanisms in normally protect us from developing cancer. However, when the finely balanced networks of interactions between proteins that control such mechanisms are disturbed, can occur.

The Cardiff team has developed a peptide-switch to alter critical interactions in B-cell lymphoma in a 'smart' and controlled way. This new pathway activation technology, called transient photoactivation, may enable scientists to identify cells normally resistant to chemotherapy leading to the development of more effective treatment strategies.

Professor Rudolf Allemann from Cardiff University's School of Chemistry, who led the research, said:

"Whilst killing cancer cells is a goal in itself, this is also proof of a wider principle. Directing therapeutic peptides to the precise location where they are required can be difficult, but activating with light will allow us to precisely define the area where we wish a peptide to act.

"Our research demonstrates that we can control cellular processes with light, which has implications for research in biology and medicine, as our tools can be used to understand the inner workings of cells and to work out how to correct misfiring pathways that lead to disease.

"This work may eventually lead to photo-controlled drugs and tools to probe molecular interactions in intact and whole organisms with enormous consequences for biomedical research."

Explore further: Experimental 'stapled peptide' drug blocks key cancer molecule

Related Stories

Stopping cancer in its tracks?

August 27, 2013

We've come a long way in cancer treatments – we have powerful, effective drugs for many types of cancer and we're moving toward ever more specific, less invasive therapies. But the problem with cancer is that it's always ...

Battling defiant leukemia cells

October 7, 2013

Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs, according to a study in The Journal of Experimental Medicine.

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.